FOLH1 and posterior cortical atrophy: Indeed, PSMA-based ligands are now considered as the “gold standard” in the imaging of PCa (Barinka et al. 2008; Chen et al. 2011; Eder et al. 2012; Hillier et al. 2013; Benesova et al. 2015; Cardinale et al. 2017a), and also their therapeutic application are ever growing, with the recent approval by FDA and EMA of the radiopharmaceutical “Pluvicto” ([177Lu]Lu-PSMA-617) (Keam 2022).